Trials / Active Not Recruiting
Active Not RecruitingNCT05891171
Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers
A Phase 1/1b Study to Evaluate the Safety and Tolerability of AB598 Monotherapy and Combination Therapy in Participants With Advanced Malignancies
- Status
- Active Not Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Arcus Biosciences, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary purpose of this study is to assess the safety and tolerability of AB598 in participants with advanced malignancies.
Conditions
- Advanced Cancer
- Advanced Malignancies
- Bladder Cancer
- Cervical Cancer
- Esophageal Cancer
- Gastric Cancer
- Gastroesophageal-junction Cancer (GEJ)
- Head and Neck Squamous Cell Carcinoma (HNSCC)
- Non-Small Cell Lung Cancer (NSCLC)
- Ovarian Cancer
- Renal Cell Carcinoma (RCC)
- Triple Negative Breast Cancer (TNBC)
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AB598 | Administered as specified in the treatment arm |
| DRUG | Zimberelimab | Administered as specified in the treatment arm |
| DRUG | Fluorouracil | Administered as specified in the treatment arm |
| DRUG | Leucovorin | Administered as specified in the treatment arm |
| DRUG | Oxaliplatin | Administered as specified in the treatment arm |
Timeline
- Start date
- 2023-10-13
- Primary completion
- 2026-03-01
- Completion
- 2026-03-01
- First posted
- 2023-06-06
- Last updated
- 2026-03-31
Locations
15 sites across 3 countries: United States, Australia, Taiwan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05891171. Inclusion in this directory is not an endorsement.